PPB Regimen Feasible as Initial Therapy for Fit Patients With NSCLC

Paclitaxel and pemetrexed with bevacizumab produced a high response rate as initial therapy in advanced lung adenocarcinomas.

Paclitaxel and pemetrexed with bevacizumab (PPB) produced a high response rate as initial therapy in treatment-naïve patients with advanced lung adenocarcinomas, a study published in the Journal of Thoracic Oncology has shown.1